髓源性抑制细胞在肺癌中的研究进展

doi:10.11904/j.issn.1002-3070.2016.03.013

摘要/Abstract

摘要： 髓源性抑制细胞(Myeloid-derived suppressor cells,MDSCs)是一群来自骨髓不成熟的异质性细胞,表型及成分复杂,在肿瘤微环境中发挥免疫抑制功能,并主要抑制T细胞免疫应答。在肺癌的发生、发展过程中,多种异常表达的细胞因子促进MDSCs增殖与激活,MDSCs活化后参与形成抑制性肿瘤免疫微环境,从而促进肿瘤细胞生长。监测MDSCs的数量与功能变化对评估肺癌的预后有重要意义。一系列针对MDSCs的干预措施在肺癌治疗中获得了重大进展,也为肺部原发及转移瘤的预防带来了希望。

关键词: 肺肿瘤, 髓源性抑制细胞, 肿瘤免疫微环境

Abstract: Myeloid-derived suppressor cells(MDSCs)are a heterogeneous mixture of immature myeloid cells,with complex phenotype and composition,harboring the ability of immune suppression in tumor microenvironment,and they mainly inhibit the function of T cells.In the development and progression of lung caner,elevated number of function activated MDSCs,arisen by various abnormal expressing cytokines,take part in tumor immune suppression microenvironment establishing so that malignant cells growth can be accelerated.Monitoring the quantity and function of MDSCs plays an important role in assessing lung neoplasm prognosis.Benefits for lung carcinoma treatment have been proved from a series of intervening measure aiming to impact MDSCs.Moreover,these means also produced a promising prospect for the prevention of primary and metastatic lung cancer.

Key words: Lung neoplasms, Myeloid-derived suppressor cells, Tumor immune microenvironment

中图分类号:

R734.2

刘洋洋, 谷飞飞, 梁金燕综述, 刘莉审校. 髓源性抑制细胞在肺癌中的研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 257-261.

LIU Yangyang,GU Feifei,LIANG Jinyan,LIU Li. Research progress of myeloid-derived suppressor cells in lung cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(3): 257-261.

参考文献

1 Siegel RL,Miller KD,Jemal A.Cancer statistics,2015[J].CA:A Cancer Journal for Clinicians,2015,65(1):5-29.
2 Remark R,Becker C,Gomez JE,et al.The non-small cell lung cancer immune contexture.A major determinant of tumor characteristics and patient outcome[J].Am J Respir Care Med,2015,191(4):377-390.
3 Gabrilovich DI,Bronte V,Chen SH,et al.The terminology issue for myeloid-derived suppressor cells[J].Cancer Research,2007,67(1):425-426.
4 Marvel D,Gabrilovich DI.Myeloid-derived suppressor cells in the tumor microenvironment:expect the unexpected[J].J Clin Invest,2015,125(9):3356-3364.
5 Damuzzo V,Pinton L,Desantis G,et al.Complexity and challenges in defining myeloid-derived suppressor cells[J].Cytometry B Clin Cytom,2015,88(2):77-91.
6 Gantt S,Gervassi A,Jaspan H,et al.The role of myeloid-derived suppressor cells in immune ontogeny[J].Front Immunol,2014,13(5):387.
7 Srivastava MK,Sinha P,Clements VK,et al.Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine[J].Cancer Research,2010,70(1):68-77.
8 Noman MZ,Desantis G,Janji B,et al.PD-L1 is a novel direct target of HIF-1,and its blockade under hypoxia enhanced MDSC-mediated T cell activation[J].J Exp Med,2014,211(5):781-790.
9 Zhong H,Gutkin DW,Han B,et al.Origin and pharmacological modulation of tumor-associated regulatory dendritic cells[J].Int J Cancer,2014,134(11):2633-2645.
10 Wu L,Du H,Li Y,et al.Signal transducer and activator of transcription 3(Stat3C)promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis[J].Am J Pathol,2011,179(4):2131-2141.
11 Li Y,Qu P,Wu L,et al.Api6/AIM/Spalpha/CD5L overexpression in alveolar type II epithelial cells induces spontaneous lung adenocarcinoma[J].Cancer Res,2011,71(16):5488-5499.
12 Wu L,Yan C,Czader M,et al.Inhibition of PPARgamma in myeloid-lineage cells induces systemic inflammation,immunosuppression,and tumorigenesis[J].Blood,2012,119(1):115-126.
13 Ortiz ML,Lu L,Ramachandran I,et al.Myeloid-derived suppressor cells in the development of lung cancer[J].Cancer Immunol Res,2014,2(1):50-58.
14 Scrimini S,Pons J,Agustí A,et al.Expansion of myeloid-derived suppressor cells in chronic obstructive pulmonary disease and lung cancer:potential link between inflammation and cancer[J].Cancer Immunology Immunother,2015,64(10):1261-1270.
15 Sinha P,Okoro C,Foell D,et al.Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells[J].J Immunol,2008,181(7):4666-4675.
16 Guedez L,Jensen-Taubman S,Bourboulia D,et al.TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis[J].J Immunother,2012,35(6):502-512.
17 Yang F,Wei Y,Cai Z,et al.Activated cytotoxic lymphocytes promote tumor progression by increasing the ability of 3LL tumor cells to mediate MDSC chemoattraction via Fas signaling[J].Cell Mol Immunol,2015,12(1):66-76.
18 Wesolowski R,Markowitz J,Carson WR.Myeloid derived suppressor cells-a new therapeutic target in the treatment of cancer[J].J Immunother Cancer,2013,1:10-20.
19 Condamine T,Kumar V,Ramachandran IR,et al.ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis[J].J Clin Invest,2014,124(6):2626-2639.
20 Zheng Y,Xu M,Li X,et al.Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells[J].Mol Immunol,2013,54(1):74-83.
21 Sawant A,Schafer CC,Jin TH,et al.Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways[J].Cancer Res,2013,73(22):6609-6620.
22 Iclozan C,Antonia S,Chiappori A,et al.Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer[J].Cancer Immunol Immunother,2013,62(5):909-918.
23 Sinha P,Parker KH,Horn L,et al.Tumor-induced myeloid-derived suppressor cell function is independent of IFN-gamma and IL-4Ralpha[J].Eur J Immunol,2012,42(8):2052-2059.
24 Guan H,Singh NP,Singh UP,et al.Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma[J].PLoS One,2012,7(4):e35650.
25 Huang A,Zhang B,Wang B,et al.Increased CD14(+)HLA-DR(-/low)myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients[J].Cancer Immunol Immunother,2013,62(9):1439-1451.
26 李慧,赵丹丹,韩淇卉,等.小细胞肺癌患者外周血中髓样抑制细胞的鉴定及临床意义研究[J].中华肿瘤杂志,2014,36(8):592-596.
27 Schneider T,Sevko A,Heussel CP,et al.Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer[J].Clin Exp Immunol,2015,180(3):467-474.
28 Heuvers ME,Muskens F,Bezemer K,et al.Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients[J].Lung Cancer,2013,81(3):468-474.
29 Vetsika E,Koinis F,Gioulbasani M,et al.A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients[J].Journal of Immunology Research,2014,2014:1-12.
30 Chen S,Liu H,Su N,et al.Myeloid-derived suppressor cells promote age-related increase of lung cancer growth via B7-H1[J].Experimental Gerontology,2015,61:84-91.
31 Shvedova AA,Tkach AV,Kisin ER,et al.Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells[J].Small,2013,9(9/10):1691-1695.
32 Shvedova AA,Kisin ER,Yanamala N,et al.MDSC and TGFbeta are required for facilitation of tumor growth in the lungs of mice exposed to carbon nanotubes[J].Cancer Res,2015,75(8):1615-1623.
33 Sceneay J,Smyth MJ,Mller A.The pre-metastatic niche:finding common ground[J].Cancer and Metastasis Reviews,2013,32(3/4):449-464.
34 Vrakas CN,O'Sullivan RM,Evans SE,et al.The Measure of DAMPs and a role for S100A8 in recruiting suppressor cells in breast cancer lung metastasis[J].Immunol Invest,2015,44(2):174-188.
35 Sangaletti S,Tripodo C,Sandri S,et al.Osteopontin shapes immunosuppression in the metastatic niche[J].Cancer Res,2014,74(17):4706-4719.
36 Otsubo D,Yamashita K,Fujita M,et al.Early-phase treatment by low-dose 5-fluorouracil or primary tumor resection inhibits MDSC-mediated lung metastasis formation[J].Anticancer Res,2015,35(8):4425-4431.
37 Horlad H,Fujiwara Y,Takemura K,et al.Corosolic acid impairs tumor development and lung metastasis by inhibiting the immunosuppressive activity of myeloid-derived suppressor cells[J].Mol Nutr Food Res,2013,57(6):1046-1054.

[1]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[2]	方振剑, 吴正琮, 郑宏宗, 敖日影, 赖国祥. CT增强对不同大小密度孤立性肺结节的诊断价值[J]. 实用肿瘤学杂志, 2018, 32(4): 333-336.
[3]	陈艳艳, 廖娇综述, 赵玉霞审校. MicroRNA-7与肺癌关系的研究进展[J]. 实用肿瘤学杂志, 2016, 30(1): 48-52.
[4]	刘亚楠, 陈莉娜, 张静, 周永芳, 李晓莉. IGF-1R和IRS-1在肺鳞癌组织中的表达及临床意义[J]. 实用肿瘤学杂志, 2015, 29(3): 225-230.
[5]	上官志毅, 胡洪涛, 陈林, 董文雷. 肺癌患者体内组织瞬间平移和旋转对立体定向放射治疗摆位的影响[J]. 实用肿瘤学杂志, 2014, 28(6): 530-534.
[6]	武丽华, 王东亮, 张艳桥. 髓源性抑制细胞——肿瘤免疫治疗的新靶点[J]. 实用肿瘤学杂志, 2012, 26(4): 369-372.
[7]	张同梅, 鲁葆华, 贾红彦, 王敬萍, 李宝兰. 肺癌患者血浆中凝血及纤溶指标的水平与其临床病理特征的关系[J]. 实用肿瘤学杂志, 2011, 25(3): 242-245.
[8]	徐珊琦, 张清媛, 汤大北, 张明辉. 原发性肺淋巴瘤15例临床分析[J]. 实用肿瘤学杂志, 2011, 25(2): 145-148.
[9]	梁大英, 谢宗涛. 非小细胞肺癌组织中NPRL2蛋白的表达及意义[J]. 实用肿瘤学杂志, 2011, 25(2): 149-152.
[10]	胡学锋, 黄国森, 张良运, 冯彦林, 谭春明. PET/CT确定非小细胞肺癌三维适形放疗靶区的临床研究^△[J]. 实用肿瘤学杂志, 2011, 25(1): 29-32.
[11]	赵静毅, 陈成诗, 滕进. 螺旋CT多平面重建支气管壁改变在中心型肺癌诊断中的价值[J]. 实用肿瘤学杂志, 2010, 24(3): 274-276.
[12]	叶小红, 张沂平. 非小细胞肺癌常见靶向药物的毒副反应研究进展[J]. 实用肿瘤学杂志, 2010, 24(2): 182-185.
[13]	于丽娟, 田墨涵, 梁秀艳, 刘蕊, 段钰, 王文志. 肺癌CT征象与Ki-67、Survivin及CyclinA表达的关系^△[J]. 实用肿瘤学杂志, 2009, 23(6): 524-527.
[14]	张春江, 刘建阳, 刘炀. 晚期肺癌心包内处理肺血管手术方法探讨[J]. 实用肿瘤学杂志, 2008, 22(6): 541-542.
[15]	洪璇;陈公琰;王萌;王彦艳;杨朝阳. 应用SELDI蛋白质芯片技术筛选肺腺癌血清标志物的研究[J]. 实用肿瘤学杂志, 2007, 21(02): 101-103,.